The most common resistance mutations in NSCLC patients treated with first and second generation ALK TKIs are G1202R, F1174X, I1171X and G1269A, and the spectrum may differ based on the ALK TKI exposure and selection pressure [23, 24, 25]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.